Oncotarget

In The News - Press Releases


Oncotarget | Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC


FOR IMMEDIATE RELEASE
2020-03-16

The cover for issue 93 of Oncotarget features Figure 2, "Comparison of overall survival (OS) and leukemia-free survival (LFS) between CloB2A1 and CloB2A2 sub-groups," by Le Bourgeois, et al.

Clo B2A2/A1 RIC regimen provides very good results for AML patients allografted in CR and could be retained as a new RIC platform for these patients.

This was a retrospective study including all patients who received a clofarabine/busulfan based RIC allo-SCT for myeloid malignancies and reported within the SFGM-TC registry.

RIC regimen consisted of clofarabine 30 mg/m /day 4 to 5 days, busulfan 3.2 mg/kg/day 2 days and 2.5 mg/kg/day of rabbit anti-thymocyte globulin 1 or 2 days.

Figure 2: Comparison of (A) overall survival (OS) and (B) leukemia-free survival (LFS) between CloB2A1 and CloB2A2 sub-groups.

Dr. Amandine Le Bourgeois and Dr. Patrice Chevallier from the Department of Hematology, CHU Hôtel Dieu, Nantes, France said, "The family of phosphatidylinositol-4-phosphate 5-kinase type-1 (PIP5K1) lipid kinases consists of three isoforms, PIP5K1A, PIP5K1B and PIP5K1C, each of which exists in multiple alternatively spliced variants."

"The family of phosphatidylinositol-4-phosphate 5-kinase type-1 (PIP5K1) lipid kinases consists of three isoforms, PIP5K1A, PIP5K1B and PIP5K1C, each of which exists in multiple alternatively spliced variants"

- Dr. Amandine Le Bourgeois & Dr. Patrice Chevallier, Department of Hematology, CHU Hôtel Dieu

The FB2A2 regimen 2.5 mg/kg/d for 2 days) was rapidly established as one of the standards of care for RIC regimen in Europe, especially in France .

Thus, the Clo B2A2 RIC regimen has been validated in a prospective phase II study including 14 patients with acute lymphoblastic leukemia, 11 with acute myeloid leukemia and 5 with myelodysplastic syndrome.

Our group retrospectively compared the Clo B2A2 versus FB2A2 RIC regimens in a cohort of patients with myeloid disease, and showed a significant OS benefit for the former in multivariate analysis.

The Le Bourgeois/Chevallier research team concluded, "CloB2A2/A1 RIC regimen provide very good results for AML patients allografted in CR and should be retained as a new RIC platform for these patients. Prospective studies are definitively needed to compare CloB2 vs FB2 RIC regimens."

Sign up for free Altmetric alerts about this article

DOI - https://doi.org/10.18632/oncotarget.26391

Full text - https://www.oncotarget.com/article/26391/text/

Correspondence to - Amandine Le Bourgeois - amandine.lebourgeois@chu-nantes.fr and Patrice Chevallier - patrice.chevallier@chu-nantes.fr

Keywords - allogeneic stem cell transplantation, clofarabine, busulfan, reduced intensity conditioning regimen, acute myeloid leukemia

About Oncotarget

Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit https://www.impactjournals.com/ or connect with @ImpactJrnls

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957x105



Copyright © 2020 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC